UNSPSC 51262407: Terbutaline

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C12H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N8ONU3L3PG, chemically known as 1,3-benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9ci) but generally known as terbutaline, which bears US NIH Compound Identifier 5403. European Medicines Agency schedules Terbutaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10915MIG.

UNSPSC 51262407 Terbutaline is a Commodity code for a specific asthma and respiratory medication, but the recent state and local opportunities posted under this code show little alignment with the nominal pharmaceutical scope. Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS (due July 26, 2023), and the Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models — neither directly addresses terbutaline procurement. State and local health departments, county health agencies, and state HHS commissions appear to be the primary issuing bodies using this code family for pharmaceutical and medical supply acquisitions, though the recent postings suggest the code may be tagged inconsistently or cover a broader pharmaceutical supply category than the specific drug name implies.

The geographic spread of recent activity includes Florida and Texas, with the Texas RFI representing preliminary market intelligence gathering rather than a committed purchase. The Seminole County opportunity, an IFB with electronic bidding through the county's e-Procurement Portal, required quarterly deliveries of naloxone and drug deactivation systems (1,900 and 800 units annually respectively) to the Seminole County Community Health Building in Sanford. Vendors had to include all shipping and delivery costs, maintain commercial general liability and workers' compensation insurance, and pass E-Verify compliance and drug-free workplace certification. The Texas HHS RFI, by contrast, explored vendor capacity for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels, with no stated budget or award value. The code shows modest recent activity with limited geographic concentration; no terbutaline-specific solicitations appear in the posted opportunities.